Abstract
Pharmacologic support of the failing neonatal heart to maintain cardiac output, which is vital for sufficient end organ perfusion, is a challenging task for the pediatric intensivist, especially since strategies which have been proven to be effective in adults cannot necessarily be extrapolated to neonates. The unique biochemical properties and structure of the neonatal heart, including the increased non-contractile tissue mass, a lower responsiveness to beta adrenergic agents and the heart rate dependent cardiac output with a limited ability toincrease stroke volume, favor some of the new inotropes of the Ca+ sensitizer family. Focusing on the after loadreduction, inodilators as phosphodiesterase inhibitors and human brain natriuretic peptide offer treatment optionsfor the neonatal myocardium. Additionally, thyroxine and steroids have been investigated in neonates with lowcardiac output after surgery for congenital heart disease. Gene therapy, in particular cardiac-selective gene transfer,might offe r perspectives for future support for the neonatal heart. This text reviews some of the most recentpharmacologic strategies targeting the failing myocardium in the critically ill newborn and infant
Mini-Reviews in Medicinal Chemistry
Title: New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Volume: 6 Issue: 7
Author(s): Alex Veldman, Stefan Rupp and Dietmar Schranz
Affiliation:
Abstract: Pharmacologic support of the failing neonatal heart to maintain cardiac output, which is vital for sufficient end organ perfusion, is a challenging task for the pediatric intensivist, especially since strategies which have been proven to be effective in adults cannot necessarily be extrapolated to neonates. The unique biochemical properties and structure of the neonatal heart, including the increased non-contractile tissue mass, a lower responsiveness to beta adrenergic agents and the heart rate dependent cardiac output with a limited ability toincrease stroke volume, favor some of the new inotropes of the Ca+ sensitizer family. Focusing on the after loadreduction, inodilators as phosphodiesterase inhibitors and human brain natriuretic peptide offer treatment optionsfor the neonatal myocardium. Additionally, thyroxine and steroids have been investigated in neonates with lowcardiac output after surgery for congenital heart disease. Gene therapy, in particular cardiac-selective gene transfer,might offe r perspectives for future support for the neonatal heart. This text reviews some of the most recentpharmacologic strategies targeting the failing myocardium in the critically ill newborn and infant
Export Options
About this article
Cite this article as:
Veldman Alex, Rupp Stefan and Schranz Dietmar, New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant, Mini-Reviews in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/138955706777698598
DOI https://dx.doi.org/10.2174/138955706777698598 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Prognostic Impact of Red Cell Distribution Width on the Development of Contrast-Induced Nephropathy, Major Adverse Cardiac Events, and Mortality in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention
Current Cardiology Reviews Inhibitory Effects of Some Bryophytes on Glutathione-S -Transferase
Current Enzyme Inhibition Smoking, Estradiol Metabolism and Hormone Replacement Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems
Current Vascular Pharmacology Associations of Body Mass Index and Obesity-Related Genetic Variants with Serum Metabolites
Current Metabolomics Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine
Endocrine, Metabolic & Immune Disorders - Drug Targets Protein Oxidative Modification in the Aging Organism and the Role of the Ubiquitin Proteasomal System
Current Pharmaceutical Design Graphical Abstracts:
Current Cardiology Reviews Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Nanofibers Based Tissue Engineering and Drug Delivery Approaches for Myocardial Regeneration
Current Pharmaceutical Design Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Blood Pressure Variability and Mortality in end Stage Renal Disease
Current Hypertension Reviews The Role of Dietary Fats in Hypertension, Obesity and Insulin Resistance: A Comparative Study of Animals and Humans in Fetal and Adult Life
Current Nutrition & Food Science Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Editorial (Hot Topic: The New Kids on the Block: Oral Direct IIa and Xa Inhibitors Enter the Proscenium of Anticoagulation Treatment)
Current Clinical Pharmacology A DNA Repair Pathway Polymorphism (rs25487) and Angiographically Proven Coronary Artery Patients in a Population of Southern Iran
Cardiovascular & Hematological Agents in Medicinal Chemistry Dietary Salt and Disease Prevention: A Global Perspective
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents